Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.
Epistemonikos ID: e2e63e656841d26b1d3b06dadcd7c4a2d479a19b
First added on: May 13, 2024